Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. - Fizazi, Karim; Azad, Arun A; Matsubara, Nobuaki; Carles, Joan; Fay, André P; De Giorgi, Ugo; Young Joung, Jae; Fong, Peter C C; Voog, Eric; Jones, Robert J; Shore, Neal D; Dunshee, Curtis; et al. (Lancet, 2025)